Xeris Pharmaceuticals, Inc(NASDAQ:XERS) 
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, re...
Website: http://www.xerispharma.com
Founded: 2005
Full Time Employees: 172
Sector: Healthcare
Industry: Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
net sales | 8,835,000 | 8,051,000 | 7,089,000 | 9,404,000 | 1,986,000 | 1,676,000 | |||||||
yoy | 344.86% | 380.37% | |||||||||||
qoq | 9.74% | 13.57% | -24.62% | 373.51% | 18.50% | ||||||||
grant and other income | 71,000 | 144,000 | 83,000 | 44,000 | 41,000 | 112,000 | |||||||
cost of goods sold | 3,383,000 | 1,826,000 | 3,407,000 | 2,832,000 | 1,299,000 | 1,790,000 | |||||||
gross profit | 5,523,000 | 6,369,000 | 3,765,000 | 6,616,000 | 728,000 | -2,000 | 261,000 | 313,000 | 297,000 | 248,000 | 801,000 | 582,000 | 819,000 |
yoy | 658.65% | -318550.00% | 1342.53% | 2013.74% | 145.12% | -100.81% | -67.42% | -46.22% | -63.74% | ||||
qoq | -13.28% | 69.16% | -43.09% | 808.79% | -36500.00% | -100.77% | -16.61% | 5.39% | 19.76% | -69.04% | 37.63% | -28.94% | |
gross margin % | 62.51% | 79.11% | 53.11% | 70.35% | 36.66% | -0.12% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
operating expenses: | |||||||||||||
research and development | 5,383,000 | 4,032,000 | 5,110,000 | 3,876,000 | 5,289,000 | 6,646,000 | 12,420,000 | 15,518,000 | 19,333,000 | 13,167,000 | 12,390,000 | 10,875,000 | 8,677,000 |
selling, general and administrative | 25,927,000 | 19,077,000 | 17,998,000 | 16,484,000 | 17,644,000 | 21,606,000 | 20,642,000 | 14,877,000 | 15,024,000 | 12,518,000 | |||
total operating expenses | 31,310,000 | 23,109,000 | 23,108,000 | 20,360,000 | 22,933,000 | 28,252,000 | |||||||
income from operations | -25,787,000 | -16,740,000 | -19,343,000 | -13,744,000 | -22,205,000 | -28,254,000 | -32,801,000 | -30,082,000 | -34,060,000 | -25,437,000 | -20,314,000 | -14,943,000 | -12,357,000 |
yoy | 16.13% | -40.75% | -41.03% | -54.31% | -34.81% | 11.07% | 61.47% | 101.31% | 175.63% | ||||
qoq | 54.04% | -13.46% | 40.74% | -38.10% | -21.41% | -13.86% | 9.04% | -11.68% | 33.90% | 25.22% | 35.94% | 20.93% | |
operating margin % | -291.87% | -207.92% | -272.86% | -146.15% | -1118.08% | -1685.80% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% |
other income: | |||||||||||||
interest and other income | 77,000 | 100,000 | 2,022,000 | 232,000 | 277,000 | 434,000 | 640,000 | 657,000 | 845,000 | ||||
interest expense | -1,795,000 | -1,791,000 | -4,591,000 | -2,328,000 | -2,242,000 | -1,499,000 | -1,531,000 | -3,507,000 | -1,062,000 | -1,063,000 | -1,055,000 | -737,000 | -562,000 |
change in fair value of warrants | -10,000 | 20,000 | 55,000 | -160,000 | -39,000 | 135,000 | 152,000 | 96,000 | -108,000 | 133,000 | 451,000 | -306,000 | |
total other income | -1,728,000 | -1,671,000 | -2,514,000 | -2,256,000 | -2,004,000 | -930,000 | -739,000 | -2,754,000 | -325,000 | 160,000 | -105,000 | 176,000 | |
net loss before benefit from income taxes | -27,515,000 | -18,411,000 | -21,857,000 | -16,000,000 | -24,209,000 | ||||||||
benefit from income taxes | 110,000 | ||||||||||||
net income | -27,515,000 | -18,411,000 | -21,857,000 | -16,000,000 | -24,099,000 | -29,184,000 | -33,082,000 | -32,836,000 | -34,385,000 | -25,277,000 | -20,419,000 | -14,767,000 | -12,987,000 |
yoy | 14.17% | -36.91% | -33.93% | -51.27% | -29.91% | 15.46% | 62.02% | 122.36% | 164.76% | ||||
qoq | 49.45% | -15.77% | 36.61% | -33.61% | -17.42% | -11.78% | 0.75% | -4.50% | 36.03% | 23.79% | 38.27% | 13.71% | |
net income margin % | -311.43% | -228.68% | -308.32% | -170.14% | -1213.44% | -1741.29% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% |
other comprehensive income, net of tax: | |||||||||||||
unrealized gains on investments | -12,000 | -17,000 | -11,000 | -125,000 | 77,000 | 49,000 | -4,000 | -23,000 | |||||
foreign currency translation adjustments | 2,000 | 1,000 | -39,000 | 17,000 | 27,000 | -32,000 | |||||||
comprehensive loss | -27,525,000 | -18,427,000 | -21,907,000 | -16,108,000 | -23,995,000 | -29,167,000 | -33,084,000 | -32,859,000 | -34,316,000 | -25,226,000 | -20,413,000 | -14,825,000 | |
net loss per common share - basic and diluted | -410 | -300 | -360 | -350 | -630 | -890 | -1,230 | -1,220 | -1,280 | -1,070 | -630 | -710 | -3,070 |
weighted-average common shares outstanding - basic and diluted | 66,367,125,000 | 42,642,901,000 | 26,110,297,000 | ||||||||||
weighted-average common shares outstanding, basic and diluted | 61,245,220,000 | 46,145,116,000 | 37,973,123,000 | 32,790,317,000 | 26,942,591,000 | 26,889,398,000 | 23,561,193,000 | 12,045,999,000 | 20,714,475,000 | 4,231,054,000 | |||
net loss before provision for/benefit from income taxes | -29,184,000 | ||||||||||||
provision for/benefit from income taxes | |||||||||||||
grant income | 210,750 | 314,000 | 314,000 | 215,000 | 754,000 | 582,000 | 819,000 | ||||||
service revenue | 12,000 | 9,000 | 6,000 | 33,000 | 47,000 | ||||||||
cost of revenue | 8,250 | 10,000 | 23,000 | ||||||||||
expense from operations | 22,609,250 | 30,395,000 | 34,357,000 | 25,685,000 | 21,115,000 | 15,525,000 | 13,176,000 | ||||||
other comprehensive loss, net of tax: | |||||||||||||
unrealized gains on short-term investments | 69,000 | 51,000 | |||||||||||
interest income | 671,000 | 817,000 | 462,000 | 238,000 | |||||||||
change in fair market value of warrants | 552,000 | ||||||||||||
general and administrative | 3,097,000 | 4,650,000 | 4,499,000 | ||||||||||
unrealized losses on short-term investments | 6,000 | -58,000 | |||||||||||
total other expense | -630,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||
current assets: | |||||||||||||
cash and cash equivalents | 63,599,000 | 66,604,000 | 37,598,000 | 37,886,000 | 102,465,000 | 39,244,000 | 19,519,000 | 56,160,000 | 66,669,000 | 61,984,000 | 45,716,000 | 75,745,000 | 134,528,000 |
short-term investments | 52,381,000 | 69,290,000 | 96,190,000 | 103,857,000 | 41,530,000 | 57,698,000 | 56,030,000 | 46,311,000 | 57,841,000 | 85,687,000 | 66,917,000 | 55,296,000 | |
trade accounts receivable | 12,295,000 | 8,938,000 | 6,875,000 | 11,928,000 | 3,171,000 | 2,531,000 | 4,693,000 | ||||||
inventory | 12,299,000 | 12,496,000 | 8,353,000 | 5,633,000 | 4,824,000 | 2,166,000 | 2,176,000 | ||||||
prepaid expenses and other current assets | 4,014,000 | 3,298,000 | 3,196,000 | 3,660,000 | 3,672,000 | 3,154,000 | 4,119,000 | 2,631,000 | 813,000 | 2,146,000 | 2,397,000 | 2,898,000 | 1,439,000 |
total current assets | 144,588,000 | 160,626,000 | 152,212,000 | 163,226,000 | 156,363,000 | 105,520,000 | 87,483,000 | 105,976,000 | 126,149,000 | 153,445,000 | 117,899,000 | 135,670,000 | 137,032,000 |
property and equipment | 6,697,000 | 6,799,000 | 6,707,000 | 6,928,000 | 7,387,000 | 7,593,000 | 7,853,000 | 7,952,000 | 7,677,000 | 7,430,000 | 2,034,000 | 1,826,000 | 1,136,000 |
other assets | 211,000 | 212,000 | 232,000 | 232,000 | 270,000 | 357,000 | 420,000 | 259,000 | 68,000 | 95,000 | 95,000 | 95,000 | 88,000 |
total assets | 151,496,000 | 167,637,000 | 159,151,000 | 170,386,000 | 165,810,000 | 116,462,000 | 108,987,000 | 128,100,000 | 133,894,000 | 160,970,000 | 120,028,000 | 137,591,000 | 138,256,000 |
liabilities and stockholders’ equity | |||||||||||||
current liabilities: | |||||||||||||
accounts payable | 5,185,000 | 4,768,000 | 3,117,000 | 4,694,000 | 4,440,000 | 3,840,000 | 5,603,000 | 1,678,000 | 1,840,000 | 1,408,000 | 866,000 | 622,000 | 556,000 |
other accrued liabilities | 19,965,000 | 13,904,000 | 15,895,000 | 11,822,000 | 13,240,000 | 13,824,000 | 18,119,000 | ||||||
accrued trade discounts and rebates | 6,799,000 | 5,719,000 | 5,984,000 | 5,758,000 | 2,412,000 | 1,719,000 | 1,375,000 | ||||||
accrued returns reserve | 3,301,000 | 2,619,000 | 2,889,000 | 3,171,000 | 2,477,000 | 2,336,000 | 1,957,000 | ||||||
other current liabilities | 214,000 | 414,000 | 322,000 | 1,582,000 | 218,000 | 161,000 | 284,000 | ||||||
total current liabilities | 35,464,000 | 27,424,000 | 28,207,000 | 27,027,000 | 22,787,000 | 21,880,000 | 27,338,000 | 17,792,000 | 21,008,000 | 13,406,000 | 10,172,000 | 8,208,000 | 9,189,000 |
long-term debt | 87,478,000 | 87,272,000 | 87,021,000 | 119,391,000 | 109,476,000 | 58,485,000 | 58,305,000 | 58,124,000 | 29,403,000 | 32,141,000 | 31,890,000 | 31,642,000 | 18,167,000 |
deferred rent | 6,769,000 | 6,692,000 | 6,629,000 | ||||||||||
other liabilities | 1,897,000 | 1,862,000 | 3,533,000 | 9,632,000 | 9,166,000 | 9,028,000 | 8,908,000 | 8,528,000 | |||||
total liabilities | 131,608,000 | 123,250,000 | 125,390,000 | 156,050,000 | 141,429,000 | 89,393,000 | 94,551,000 | 84,444,000 | 59,103,000 | 53,870,000 | 44,622,000 | 42,471,000 | 28,919,000 |
commitments and contingencies | |||||||||||||
stockholders’ equity: | |||||||||||||
preferred stock—par value 0.0001... | |||||||||||||
common stock—par value 0.0001... | 7,000 | 7,000 | 6,000 | 5,000 | 5,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 |
additional paid in capital | 403,212,000 | 400,186,000 | 371,134,000 | 329,803,000 | 323,740,000 | 302,434,000 | 260,635,000 | 256,771,000 | 255,047,000 | 253,040,000 | 196,121,000 | 195,422,000 | 194,813,000 |
accumulated deficit | -383,311,000 | -355,796,000 | -337,385,000 | -315,528,000 | -299,528,000 | -275,429,000 | -246,245,000 | -213,163,000 | -180,327,000 | -145,942,000 | -120,665,000 | -100,246,000 | -85,478,000 |
accumulated other comprehensive income | -20,000 | -10,000 | 6,000 | 56,000 | 164,000 | 60,000 | |||||||
total stockholders’ equity | 19,888,000 | 44,387,000 | 33,761,000 | 14,336,000 | 24,381,000 | 27,069,000 | 14,436,000 | 43,656,000 | 74,791,000 | 107,100,000 | 75,406,000 | 95,120,000 | 109,337,000 |
total liabilities and stockholders’ equity | 151,496,000 | 167,637,000 | 159,151,000 | 170,386,000 | 165,810,000 | 116,462,000 | 108,987,000 | 128,100,000 | 133,894,000 | 160,970,000 | |||
investments | 1,790,000 | 2,992,000 | 13,231,000 | 13,913,000 | |||||||||
other accounts receivable | 262,000 | 701,000 | 727,000 | 946,000 | |||||||||
accumulated other comprehensive gain | 43,000 | 45,000 | 68,000 | ||||||||||
accounts receivable | 874,000 | 826,000 | 3,628,000 | 2,869,000 | 1,731,000 | 1,065,000 | |||||||
accrued expenses | 15,706,000 | 15,609,000 | 11,482,000 | 8,214,000 | 6,260,000 | 7,542,000 | |||||||
warrant liabilities | 302,000 | 403,000 | 295,000 | 860,000 | 1,042,000 | 807,000 | |||||||
deferred grant awards | 106,000 | 156,000 | 221,000 | 232,000 | |||||||||
current portion of long-term debt | 3,000,000 | ||||||||||||
other long-term liabilities | 8,692,000 | 8,323,000 | 2,560,000 | 2,621,000 | 1,563,000 | ||||||||
accumulated other comprehensive loss | -1,000 | -52,000 | -58,000 | ||||||||||
liabilities, convertible preferred stock and stockholders’ equity | |||||||||||||
convertible preferred stock: | |||||||||||||
series a convertible preferred stock—par value 0.0001... | |||||||||||||
series b convertible preferred stock—par value 0.0001... | |||||||||||||
series c convertible preferred stock—par value 0.0001... | |||||||||||||
total convertible preferred stock | |||||||||||||
stockholders’ equity | |||||||||||||
total liabilities, convertible preferred stock and stockholders’ equity | 120,028,000 | 137,591,000 | 138,256,000 | ||||||||||
deferred grant award | 284,000 | 284,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | ||||||||||||
net loss | -27,515,000 | -18,411,000 | -21,857,000 | -16,000,000 | -24,099,000 | -29,184,000 | -33,082,000 | -32,836,000 | -34,385,000 | -25,277,000 | -20,419,000 | -14,767,000 |
adjustments to reconcile net loss to net cash from operating activities: | ||||||||||||
depreciation and amortization | 320,000 | 337,000 | 446,000 | 383,000 | 318,000 | 320,000 | 380,000 | 339,000 | 225,000 | 134,000 | 174,000 | 5,000 |
amortization of investments | 126,000 | 154,000 | 137,000 | 44,000 | -22,000 | -75,000 | -78,000 | |||||
amortization of debt issuance costs | 241,000 | 251,000 | 273,000 | 345,000 | 182,000 | 180,000 | 181,000 | 254,000 | 262,000 | 251,000 | 248,000 | 156,000 |
stock-based compensation | 2,512,000 | 2,461,000 | 2,140,000 | 2,054,000 | 2,071,000 | 2,008,000 | 1,842,000 | 1,794,000 | 1,701,000 | 1,147,000 | 579,000 | 544,000 |
loss on extinguishment of debt | 0 | 0 | 0 | |||||||||
change in fair value of warrants | 10,000 | -20,000 | -55,000 | 160,000 | 39,000 | -135,000 | -152,000 | -96,000 | 108,000 | -552,000 | -133,000 | -451,000 |
changes in operating assets and liabilities: | ||||||||||||
trade accounts receivable | -3,357,000 | -2,063,000 | 5,053,000 | -8,757,000 | -640,000 | 2,162,000 | ||||||
prepaid expenses and other current assets | 957,000 | -15,000 | 430,000 | -1,635,000 | 1,033,000 | 1,097,000 | -726,000 | -1,818,000 | 1,333,000 | 251,000 | 501,000 | -1,460,000 |
inventory | -404,000 | -3,482,000 | -1,686,000 | -809,000 | -2,658,000 | 10,000 | ||||||
accounts payable | 417,000 | 1,651,000 | -1,577,000 | 270,000 | 600,000 | -1,779,000 | 3,925,000 | -162,000 | 432,000 | 542,000 | 244,000 | 66,000 |
other accrued liabilities | 3,372,000 | -2,790,000 | 4,278,000 | 807,000 | -2,589,000 | -4,703,000 | ||||||
accrued trade discounts and rebates | 1,080,000 | -265,000 | 226,000 | 3,346,000 | 693,000 | 344,000 | ||||||
accrued returns reserve | 682,000 | -270,000 | -282,000 | 694,000 | 141,000 | 379,000 | ||||||
other | 1,537,000 | -1,494,000 | 612,000 | 1,685,000 | ||||||||
net cash from operating activities | -20,022,000 | -23,956,000 | -10,869,000 | -16,985,000 | -23,759,000 | -28,945,000 | -29,572,000 | -21,154,000 | -18,335,000 | -15,917,000 | ||
cash flows from investing activities: | ||||||||||||
capital expenditures | -218,000 | -429,000 | -225,000 | 20,000 | -146,000 | -26,000 | -244,000 | -200,000 | -250,000 | -771,000 | ||
free cash flows | -20,240,000 | -24,385,000 | -11,094,000 | -16,965,000 | -23,905,000 | -28,971,000 | -29,816,000 | -21,354,000 | -18,585,000 | -16,688,000 | ||
purchases of investments | -12,226,000 | -7,920,000 | -10,365,000 | -77,694,000 | 0 | -13,714,000 | -26,497,000 | |||||
sales and maturities of investments | 29,000,000 | 34,650,000 | 17,839,000 | 17,000,000 | 17,490,000 | 22,416,000 | 17,700,000 | |||||
net cash from investing activities | 16,556,000 | 26,301,000 | 7,249,000 | -60,674,000 | 17,344,000 | 8,676,000 | -9,041,000 | -18,725,000 | -11,723,000 | -56,049,000 | ||
cash flows from financing activities: | ||||||||||||
proceeds from equity offerings | 0 | 27,000,000 | 0 | 3,019,000 | ||||||||
payments of equity offering costs | -23,000 | -275,000 | ||||||||||
proceeds from issuance of debt | 3,500,000 | 11,249,000 | 0 | |||||||||
payments of debt | 1,000 | |||||||||||
payments of debt issuance costs | -57,000 | -981,000 | -41,000 | 0 | ||||||||
proceeds from employee stock purchase plan | ||||||||||||
proceeds from exercise of stock awards | 140,000 | 26,000 | 22,000 | 50,000 | 0 | 30,000 | 50,000 | 72,000 | 78,000 | 63,000 | ||
repurchase of common stock withheld for taxes | 0 | -365,000 | 0 | 0 | 0 | -63,000 | ||||||
net cash from financing activities | 460,000 | 26,661,000 | 3,326,000 | 13,063,000 | 69,608,000 | 40,067,000 | 1,970,000 | 22,570,000 | -157,000 | 56,147,000 | 29,000 | 13,183,000 |
effect of exchange rate changes on cash and cash equivalents | 6,000 | 17,000 | 28,000 | -73,000 | ||||||||
increase in cash and cash equivalents | -3,005,000 | 29,006,000 | -288,000 | -64,579,000 | 63,221,000 | 19,725,000 | -36,641,000 | -10,509,000 | 4,685,000 | 16,268,000 | -30,029,000 | -58,783,000 |
cash and cash equivalents, beginning of period | 0 | 37,598,000 | 0 | 0 | 0 | 19,519,000 | 0 | 0 | 0 | 45,716,000 | 0 | 0 |
cash and cash equivalents, end of period | -3,005,000 | 66,604,000 | -288,000 | -64,579,000 | 63,221,000 | 39,244,000 | -36,641,000 | -10,509,000 | 4,685,000 | 61,984,000 | -30,029,000 | -58,783,000 |
supplemental schedule of cash flow information: | ||||||||||||
cash paid for interest | 967,000 | 2,238,000 | 878,000 | 882,000 | 1,477,000 | 1,318,000 | 905,000 | 1,174,000 | 1,105,000 | 533,000 | 680,000 | 580,000 |
supplemental schedule of non-cash investing and financing activities: | ||||||||||||
accrued debt issuance costs | 48,000 | -369,000 | -41,000 | -484,000 | 0 | 2,325,000 | 0 | 900,000 | ||||
other accounts receivable | 428,000 | 4,000 | 252,000 | |||||||||
other assets | 46,000 | -221,000 | -53,000 | 0 | -7,000 | |||||||
accrued equity offering costs | 56,000 | |||||||||||
loss on conversion of convertible debt | ||||||||||||
deferred rent | 409,000 | 390,000 | 102,000 | 39,000 | 134,000 | |||||||
repayment of debt | 0 | |||||||||||
payments of debt conversion costs | ||||||||||||
proceeds from issuance of employee stock purchase plan shares | 284,000 | |||||||||||
tenant improvement allowance | 150,000 | 0 | ||||||||||
issuance of stock for conversion of debt | 36,752,000 | |||||||||||
accrued public equity offering costs | ||||||||||||
other liabilities | 133,000 | 1,190,000 | 18,000 | -1,000 | 32,000 | |||||||
proceeds from public offerings | 42,744,000 | |||||||||||
payments of public offering costs | -2,614,000 | -444,000 | -3,894,000 | |||||||||
deferred public offering costs within other accrued liabilities | 269,000 | |||||||||||
proceeds from initial public offering | 0 | 0 | ||||||||||
payments for initial public offering costs | -49,000 | -1,785,000 | ||||||||||
proceeds from sale of series c preferred stock | 0 | 0 | ||||||||||
payments of series c preferred stock offering costs | 0 | 0 | ||||||||||
allocation of debt costs to warrants | 0 | |||||||||||
accounts receivable | -170,000 | 2,074,000 | -31,000 | -1,138,000 | -666,000 | |||||||
accrued expenses | -379,000 | 5,119,000 | 2,452,000 | 1,840,000 | 529,000 | |||||||
deferred grant awards | -50,000 | -65,000 | -11,000 | |||||||||
proceeds from follow-on public offering | ||||||||||||
payments of follow-on public offering costs | ||||||||||||
stock purchases from employee stock purchase plan | ||||||||||||
deferred public offering costs within accrued expenses | 444,000 | |||||||||||
vesting of early exercised awards | 15,000 | 20,000 | 56,000 | 42,000 | 52,000 | |||||||
non-cash exercise of warrants | ||||||||||||
amortization of short-term investments | -257,000 | -194,000 | ||||||||||
net cash used by operating activities | ||||||||||||
purchases of short-term investments | -8,445,000 | -37,815,000 | -13,573,000 | |||||||||
sales and maturities of short-term investments | 36,618,000 | 19,290,000 | ||||||||||
net cash provided (used) by investing activities | ||||||||||||
proceeds from the issuance of common stock from public offering | 1,000 | 59,969,000 | ||||||||||
proceeds from issuance of long-term debt | 0 | 15,000,000 | ||||||||||
purchases from employee stock purchase plan | ||||||||||||
deferred initial public offering costs within accrued expenses | ||||||||||||
purchases of property and equipment | -200,000 | -250,000 | -771,000 | |||||||||
tenant improvements | 5,508,000 | |||||||||||
deferred grant award | 0 | |||||||||||
changes in operating assets and liabilities | ||||||||||||
payment of debt issuance costs | ||||||||||||
allocation of debt proceeds to warrants |